Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Aduro Biotech (ADRO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 256,138
  • Shares Outstanding, K 80,043
  • Annual Sales, $ 15,090 K
  • Annual Income, $ -95,360 K
  • 60-Month Beta 2.05
  • Price/Sales 16.66
  • Price/Cash Flow N/A
  • Price/Book 2.17

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.17
  • Number of Estimates 6
  • High Estimate 0.22
  • Low Estimate -0.28
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +45.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.82 +13.48%
on 05/14/19
4.59 -30.28%
on 05/07/19
-0.37 (-10.36%)
since 04/24/19
3-Month
2.82 +13.48%
on 05/14/19
4.59 -30.28%
on 05/07/19
-0.89 (-21.76%)
since 02/22/19
52-Week
2.34 +36.75%
on 01/29/19
9.00 -64.44%
on 06/01/18
-5.05 (-61.21%)
since 05/24/18

Most Recent Stories

More News
Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting

Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL)...

NVS : 87.52 (+3.65%)
ADRO : 3.20 (+1.91%)
Aduro Biotech Announces Clinical Program Update for Anti-APRIL Antibody BION-1301

-- First healthy volunteer cohort cleared in Phase 1 first-in-human study of BION-1301 for the treatment of IgA nephropathy (IgAN); initial data in healthy volunteers expected in H1 2020 and IgAN patients...

ADRO : 3.20 (+1.91%)
Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates

Aduro (ADRO) suspends the BION-1301 program for MM in Q1 due to severe competition.

MRK : 81.17 (+0.19%)
NVS : 87.52 (+3.65%)
ADRO : 3.20 (+1.91%)
BMY : 46.81 (-1.04%)
Aduro Biotech (ADRO) Reports Q1 Loss, Misses Revenue Estimates

Aduro Biotech (ADRO) delivered earnings and revenue surprises of -70.59% and -51.23%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

ADRO : 3.20 (+1.91%)
Aduro Biotech: 1Q Earnings Snapshot

BERKELEY, Calif. (AP) _ Aduro Biotech Inc. (ADRO) on Tuesday reported a loss of $23.4 million in its first quarter.

ADRO : 3.20 (+1.91%)
What's in Store for Axsome (AXSM) This Earnings Season?

On Axsome's (AXSM) first-quarter earnings call, investors will look for its progress with the CNS pipeline candidates and the regulatory updates on the same.

HZNP : 24.83 (+0.93%)
GSK : 40.18 (+0.48%)
ADRO : 3.20 (+1.91%)
AXSM : 24.73 (+4.92%)
Aduro Biotech Reports First Quarter 2019 Financial Results

Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL)...

ADRO : 3.20 (+1.91%)
Guardant Health (GH) to Report Q1 Earnings: What's in Store?

At Guardant Health's (GH) Q1 conference, investors will watch out for the updates on liquid biopsy-based Guardant360 and GuardantOMNI tests that could help detect advanced stages of cancer.

GH : 77.00 (+1.57%)
AZN : 39.02 (+0.93%)
HZNP : 24.83 (+0.93%)
ADRO : 3.20 (+1.91%)
Proteostasis (PTI) to Post Q1 Earnings: What's in Store?

During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.

PTI : 1.02 (+2.00%)
HZNP : 24.83 (+0.93%)
VRTX : 171.77 (-0.72%)
ADRO : 3.20 (+1.91%)
Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?

During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.

HZNP : 24.83 (+0.93%)
CLVS : 16.74 (+0.97%)
SLNO : 2.23 (+4.21%)
ADRO : 3.20 (+1.91%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 48% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators mostly agree with the trend.

See More Share

Trade ADRO with:

Business Summary

Aduro Biotech, Inc. is an immunotherapy company. The Company develops technology and vaccines for the treatment of cancer and mesothelin-expressing tumors. Its product pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX which are in different clinical trial. Aduro Biotech, Inc. is...

See More

Key Turning Points

2nd Resistance Point 3.33
1st Resistance Point 3.27
Last Price 3.20
1st Support Level 3.09
2nd Support Level 2.97

See More

52-Week High 9.00
Fibonacci 61.8% 6.46
Fibonacci 50% 5.67
Fibonacci 38.2% 4.88
Last Price 3.20
52-Week Low 2.34

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar